Physician profile
Komal Dang
NPI 1669443602
$1,977.04
in general payments reported to CMS, 2019-2025
19 companies · $29.27 in 2025
The $29.27 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,113 · 2020: $710 · 2021: $125 · 2025: $29.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $29.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $29.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $389.94 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $264.91 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $214.85 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $186.40 | 2019-2020 | |
| Glaxosmithkline, LLC. | $177.36 | 2019-2020 | |
| Lilly USA, LLC | $129.04 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.63 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $85.47 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $79.02 | 2020 | |
| Pfizer INC. | $78.89 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.65 | 2019 | |
| Amgen INC. | $32.69 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $32.08 | 2020 | |
| Merck Sharp & Dohme LLC | $31.39 | 2019-2020 | |
| Abbott Laboratories | $29.27 | 2025 | Freestyle Libre 3 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.42 | 2019 | |
| Allergan, INC. | $25.84 | 2019 | |
| Genzyme Corporation | $22.37 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Komal Dang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.